Live
Endpoints NewsFDA delays Leqembi decision; Artiva raises $300M; Pharvaris prices offeringCellFronto-insular circuit mechanisms of accelerated intermittent theta burst stimulationCellA blood-brain barrier-like vascular gate limits immunotherapy efficacy in neuroendocrine cancersCellA cell type-specific mechanism driving the rapid antidepressant effects of transcranial magnetic stimulationFierceBiotechAnalysts cut enGene cancer sales forecast after updated data widen gap to J&JBioPharma DiveFDA to reevaluate spurned cell therapy; Under-the-skin Leqembi review extended10x Genomics News10x Genomics Q1 Earnings & Revenues Beat Estimates, Gross Margin Up - Zacks Investment ResearchEli LillyWill Eli Lilly Be the First $2 Trillion Healthcare Stock? 3 Catalysts That Could Get It There. - The Motley FoolAbbottAbbott's Medical Device Strategy Supports Long-Term Growth Outlook - The Globe and MailFDA News ReleasesFDA Issues Guidance to Improve Collection of Pregnancy Safety Data for Drugs and BiologicsBioPharma DiveLilly, Gilead lead pharma’s M&A boomEndpoints News'Pharma, not really’: Top young AI talent shuns careers at big drugmakers

Archive

Latest Oldest Clear
@Agilent
Total 513
Source Agilent
Query --